Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according ...

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

It can generally be classified into 5 main subtypes. The first is large vessel vasculitides (ie, giant cell arthritis), with the second being medium vessel vasculitis (ie, Kawasaki disease). AAV forms ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1Safety in GCA patients was consistent with known safety profile o ...

Autoimmune vasculitis is a group of conditions, such as giant cell arteritis and Kawasaki disease, that cause blood vessel inflammation. Learn more here.

A similar pathological sequence leading to arterial stenosis can occur in other types of vasculitis, such as Takayasu’s arteritis (TAK) and Giant cell arteritis (GCA) (Weyand and Goronzy, 2013; ...

Results from the SELECT-GCA study showed upadacitinib (Rinvoq) induced significant and sustained remission in people with new-onset or relapsing giant cell arteritis.